Mutual of America Capital Management LLC Acquires 1,604 Shares of Enovis Co. (NYSE:ENOV)

Mutual of America Capital Management LLC grew its holdings in shares of Enovis Co. (NYSE:ENOV) by 5.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 30,183 shares of the company’s stock after acquiring an additional 1,604 shares during the period. Mutual of America Capital Management LLC’s holdings in Enovis were worth $1,299,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. lifted its holdings in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares during the period. Aigen Investment Management LP lifted its stake in shares of Enovis by 5.1% in the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock worth $381,000 after acquiring an additional 430 shares during the period. Ridgewood Investments LLC bought a new stake in Enovis in the second quarter valued at approximately $44,000. State of Alaska Department of Revenue increased its position in Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock valued at $279,000 after purchasing an additional 1,115 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in Enovis during the 3rd quarter worth approximately $55,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV opened at $48.27 on Tuesday. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The company has a market cap of $2.70 billion, a PE ratio of -22.04 and a beta of 1.91. The stock has a 50-day moving average of $42.70 and a 200-day moving average of $44.92. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter last year, the firm posted $0.56 earnings per share. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. On average, equities research analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. JMP Securities initiated coverage on Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. Finally, Evercore ISI cut their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.